Prognostic Impact of miR-224 and RAS Mutations in Medullary Thyroid Carcinoma

Table 1

Clinical, pathological, and molecular data on MTC cases.

	MTC
Total number	134
Gender
Male	54/134 (37%)
Female	80/134 (43%)
Median age (95%CI)	58.5 (55–61)
Median follow-up in months (95%CI)	40 (32–42)
Median calcitonin level in pg/ml at diagnosis (95%CI)	466 (5.5–22931)
Stage
I	62/134 (46%)
II	26/134 (19%)
III	13/134 (10%)
IV	33/134 (25%)
Lymph node involvement
Present	46/134 (34%)
Absent	88/134 (66%)
Distant metastases
Present	12/134 (9%)
Absent	122/134 (91%)
Germline RET mutation
Present	27/134 (20%)
Absent	107/134 (80%)
Sporadic RET mutation
Present	39/107 (36%)
Absent	68/107 (64%)
Sporadic RAS mutation
Present	10/107 (9%)
Absent	94/107 (91%)
Biochemical cure^1
Present	86/133 (65%)
Absent	35/133 (35%)
Disease progression
Present	17/133 (13%)
Absent	116/133 (87%)
Disease-related death^2	9/132 (7%)

¹Ct level was unavailable for one patient. ²Two patients were lost to follow-up.